A phase I study to assess the local and systemic safety and tolerability of MRG-110 after intradermal injection

Trial Profile

A phase I study to assess the local and systemic safety and tolerability of MRG-110 after intradermal injection

Planning
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs MRG-110 (Primary)
  • Indications Heart failure; Ischaemia
  • Focus Adverse reactions
  • Sponsors miRagen Therapeutics
  • Most Recent Events

    • 03 Apr 2018 New trial record
    • 27 Mar 2018 According to a miRagen Therapeutics media release, the company recently filed an investigational new drug application, or IND, for this study which it expects to initiate in the first half of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top